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OBITUARY 
 
Dr Stewart Sanders Adams 
(16-04-1923---30-01-2019 
 
Pioneer in the discovery of ibuprofen, that from meagre beginnings to become 
world’s best-selling pain-killing drug 
 
 
It is with much sadness that we record the death of Dr Stewart Sanders Adams aged 95. He 
has become known as the ‘father of ibuprofen’, having been leader of the team in Boots 
Research Department, Nottingham, that discovered and developed ibuprofen the popular 
world-wide drug for the treatment of inflammation, pain and fever.  Initially, the drug was 
developed for treating rheumatoid arthritis and later other arthritic and painful conditions. 
After proof of its safety it later became a popular non-prescription analgesic.  Readers of 
this journal will observe that aspects of the therapeutics, mechanisms of action and side-
effects ibuprofen has frequently been reported (see Publications below)   
 
Stewart was born in Byfield (a town in the English midland county of Northamptonshire) on 
16th April 1923, the son of a railwayman and was educated at Doncaster and March 
Grammar schools (Yorkshire).  He left in 1939 age 16 to begin an apprenticeship in the local 
Boots pharmacy.  After 3 years in retail pharmacy he decided his future was in biological 
research and he graduated BPharm from the University College Nottingham in 1945.  His 
first job was in Boots penicillin production unit in the early days of the development of 
penicillin.  It was produced by surface culture in which the penicillium mould was grown in 
quart milk bottles.  The work though important, was rather routine, so Adams in 1947 
moved to the Pharmacology Division of the Research Department.  His first research interest 
was in the anticoagulant heparin and in 1948 he developed a unique assay for heparin much 
superior to that then employed, which became the recommended method in the British 
Pharmacopoeia. He developed an interest in the anti-lipaemic (fat-reducing) properties of 
heparin and aimed to develop a heparinoid with maximal anti-lipaemic and minimal anti-
coagulent properties for use in patients with heart disease.  A series of such compounds 
were produced by sulphating polysaccharide extracts from Laminaria seaweeds was 
investigated.  However, the best of these was found to be too toxic in early clinical trials and 
was hence abandoned. 
 
Other studies in heparin led him to believe that heparin and histamine co-existed in the 
mast cell and he continued these and related studies in the pharmacology department at 
Leeds University where he obtained a PhD. 
 
In 1952 he re-joined Boots Research Dept to work on rheumatoid arthritis.  The 
pharmacology division was housed in a group of rambling buildings on the outskirts of 
Nottingham having moved there at the beginning of WW2 from the city centre as a 
precaution against bombing; this proved a wise move since part of the research department 
was destroyed in an air raid in 1941.  The first six years of his research (1953—1959) was 
carried out under challenging conditions since his laboratory was one of the 2 front rooms 
of a terraced house in West Bridgford.  He began with one technician (Colin Burrows, who 
became a life-long colleague).  In 1953, the only drugs of proven value in the treatment of 
rheumatoid arthritis were cortisone–like, very high doses of aspirin and phenylbutazone. 
However, these produced side-effects particularly gastric injury, so Adams saw the need for 
a non-cortisone-like compound but with anti-rheumatic properties that would be well 
tolerated particularly by the gut.  He was one of the first investigators in this field and these 
compounds later became known and widely uses as non-steroidal anti-inflammatory drugs 
(NSAIDS).   
 
Aspirin was known to be an analgesic and anti-pyretic (pain and fever) bit its anti-
inflammatory effects were not generally recognised at that.   
 
Adams became convinced, that the analgesic effects of aspirin were due entirely to its anti-
inflammatory properties and began a search for a suitable animal model to demonstrate 
this specific effect.  Eventually, he found a simple type of inflammation model, the UV 
erythema in the guinea pig (mild “sunburn”), which he discovered could be inhibited by oral 
doses of aspirin.  He showed that there was a difference between paracetamol and aspirin 
since the former did not possess anti-inflammatory activity and was hence less effective in 
rheumatic diseases.  Although aspirin had been in clinical use since 1900, no analogues had 
ever been tested for anti-inflammatory action. In a seminal internal report in 1956, Adams 
outlined his plans for future work which included a chemical programme to explore this.  He 
was joined by the late Dr John Nicholson an organic chemist and they made and tested over 
200 analogues but to their great disappointment none was superior to aspirin.  However, 
these aspirin studies led Nicholson to a group of compounds chemically related to selective 
weed-killers.  The most potent of these possessed high anti-inflammatory activity but failed 
in clinical trials in rheumatoid arthritis.  Hence, the early concept of the primacy of acute 
anti-inflammatory activity was modified by the inclusion of additional tests.  Further 
chemical modification by Nicholson led to new compounds (phenyl acetic acids) three of 
which were active in clinical trials in rheumatoid arthritis, but unfortunately all had 
unacceptable side-effects.  Studies were performed with radioactively-labelled drugs to 
determine their biodisposition in dogs. These studies led, to the identification of closely-
related propionic acids (phenyl-propionic acids), being a large group of active compounds 
might be better tolerated in the liver.  Although ibuprofen was not the most active in the 
group, it was selected for being less toxic. It proved to be effective and well-tolerated in 
clinical trials and in wider use. Detailed history of the discovery of ibuprofen is shown in 
Table 1). 
 
After extensive clinical investigations with ibuprofen in rheumatic conditions (as BrufenTM) 
evidence accumulated that it was relatively safe, especially at daily doses of 1200-
2400mg/day. It was introduced in the UK as a prescription anti-rheumatic in 1969. A major 
development then proceeded in 1983, after further additional studies and safety data, as it 
was the first NSAID to be approved in the UK and next year in the USA as an over-the-
counter (OTC) non-prescription drug for treatment of mild to moderate pain and fever. 
Much of the efforts in enabling the drug to be accepted as an OTC drug goes to Dr Mervyn 
Busson, who as Director of Medical Services was responsible for clinical development of OTC 
ibuprofen. Now over 30,000 tons of drug is produced world-wide annually where it is 
marketed in a variety of formulations and trade mark names. The success of ibuprofen in 
being developed in so many formulations is in many ways due to its unique chemistry. It’s 
relative safety is undoubtedly also related to its special chemical properties. Today the fact 
that it is used as a basis for comparison with newer anti-inflammatory drugs and natural 
products gives credence for it being regarded as a ‘bench-mark’ for comparison. Many of 
these advances would never have been realised back in the early years of the discovery by 
Adams and his team,  not have been possible without his unending perseverance and 
determination. 
 
The propionic series was investigated further resulting in the development of a more potent 
propionic acid, the NSAID flurbiprofen (FrobenTM) in 1977.  It was launched on  
a rather crowded NSAID market somewhat late, but has been useful in various painful 
conditions, including bone pain. It has been explored for potentially unique pharmacological 
properties among then certain cancers.  
 
Adams retired in 1983,  but continued with his interest in ibuprofen and lectured widely on 
this and related topics. 
 
He was appointed OBE in 1988 and awarded an honorary doctorate of science by the 
University of Nottingham in 2008.  He was made an Honorary Freeman of the City of 
Nottingham in 2013.  The only other Boots employee to be so honoured was Jesse Boot 
himself.  His work undoubtedly contributed to the Boots Company  
 
He had been a keen sportsman and rugby player and was a member of Nottingham County 
Cricket Club and Nottingham Forest Football Club.  He read widely with a special interest in 
modern European history and politics, and was most knowledgeable in these fields.  
 
In 1950 he married Mary Harvey a fellow researcher in the Boots Research Department, 
who died in 2010. They had 2 sons one of whom (David) is a Pro-Vice Chancellor and Dean 
of Research at the University of Nottingham and an international expert on liver disease, 
while the other (Chris) a successful solicitor in Nottingham.  
 
On a personal note, I should like to record my sincere appreciation to Stewart for his long-
standing help, advice and guidance on matters related to the discovery and development of 
ibuprofen. He was a humble person, had great humility, and recognized the contributions of 
many others both in the Boots Company as well as collaborators and those who published 
widely on the drug as well as on inflammatory processes.  
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